Globalworld globe
United Kingdom
North America
Europe
  • facebook
  • linkedin
Medical Developments International
  • Home
  • Products
    • Asthma & COPD
  • About
    • Distributor Information
    • Careers
    • Associations
  • Investors/Media
    • Financial Reports
    • Board of Directors/Management
    • Corporate Governance
    • Media Centre
    • Diversity Policy
    • Share Trading Policy
  • Contact

News

MVP completes European Distribution deal with Mundipharma

Sep 14, 2015Mark EdwardsNews

14 September 2015

ASX ANNOUNCEMENT

Mundipharma and Medical Developments International announce a new alliance for the commercialisation of Penthrox® in Europe

Cambridge, UK and Victoria, Australia, September, 14th 2015  Mundipharma International Corporation Limited (Mundipharma) and Medical Developments International Limited (ASX: MVP) today announced that they have entered into a License, Development and Commercialisation Agreement for Penthrox® (low dose methoxyflurane) in Europe, as a self-inhaled analgesic for the treatment of emergency pain.

For more information please click on the following link – MVP completes European Distribution deal with Mundipharma

Contact Us

for information on our range of products

Find a distributor

in our global network

Investors

invest in a company with
innovative foresight

News

  • FY23 ASX Announcement

    31 August 2023 ASX Announ...

  • Medical Developments International Ltd awarded up to $1.5M in funding for next generation Penthrox® device

    Media Announcment Medical...

  • FY23 Half Year ASX Announcement

    24 February 2023 ASX Anno...

Healthcare Professional Registration

Login to access healthcare professional resources



Remember Me

Forgot password? | Register

Medical Developments International

Address:
4 Caribbean Drive, Scoresby,
Victoria, 3179
Australia
Phone: +61 3 9547 1888
Email: [email protected]
ABN: 14 106 340 667
For Medical Enquiries:

Phone: 1800 PENTHROX (1800 736 847)
Email: [email protected]

Email Newsletter